FDA Drug Recalls

Recalls / Class II

Class IID-0359-2019

Product

Sandoz Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg, 1000-count bottles, Rx Only, Finished Drug Product Manufactured by: Lek Pharmaceuticals d.d. SI-1526 Ljubljana,Sovenia for Sandoz Inc., Princeton, NJ 08540, NDC 0781-5207-10.

Affected lot / code info
Lot #: JB8912; Exp. 06/2020

Why it was recalled

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Recalling firm

Firm
Sandoz, Inc
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
506 Carnegie Ctr Ste 400, N/A, Princeton, New Jersey 08540-6243

Distribution

Quantity
170 HDPE bottles
Distribution pattern
OH, PR

Timeline

Recall initiated
2018-11-01
FDA classified
2019-01-14
Posted by FDA
2018-12-05
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0359-2019. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.